Magnetic field-assisted gene delivery: Achievements and therapeutic potential

Current Gene Therapy

Volumn 12, Issue 2, 2012, Pages 116-126

  Schwerdt, José I ^a   Goya, Gerardo F ^b   Calatayud, M Pilar ^b   Hereñú, Claudia B ^a   Reggiani, Paula C ^a   Goya, Rodolfo G ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Gene delivery; Magnetic gene targeting; Magnetic nanoparticles; Magnetofection; Minimal invasiveness nanomedicine

Indexed keywords

BETA INTERFERON; CYTOKINE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 4; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MAGNETIC NANOPARTICLE; ONCOLYTIC ADENOVIRUS; P55TNFR IG PROTEIN; P75TNFR IG PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CELL CULTURE; EXPERIMENTAL MODEL; GENE TARGETING; GENE THERAPY; GENE VECTOR; HEART INFARCTION; HUMAN; LIVER CELL CARCINOMA; MAGNETOTHERAPY; NEOPLASM; NERVE DEGENERATION; NONHUMAN; STENT THROMBOSIS;

CELLS, CULTURED; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; MYOCARDIAL INFARCTION; NEOPLASMS; NEURODEGENERATIVE DISEASES;

ANIMALIA;

EID: 84860277486     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312800099616     Document Type: Article

References (98)

1. Widder KJ, Senyel AE, Scarpelli GD. Magnetic microspheres: A model system of site specific drug delivery in vivo. Proc Soc Exp Biol Med 1978; 158: 141-46.
2. Lübbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 1996; 56: 4686-93.
3. Lübbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res 2001; 95: 200-6.
4. Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002; 9: 102-9.
5. Plank C, Zelphati O, Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-Progress and prospects. Adv Drug Deliv Rev 2011; 63: 1300-31.
6. Huth S, Lausier J, Gersting SW, et al. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 2004; 6: 923-36.
7. Tresilwised N, Pithayanukul P, Mykhaylyk O, et al. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol Pharm 2010; 7:1069-89.
8. Kamei K, Mukai Y, Kojima H, et al. Direct cell entry of gold/ironoxide magnetic nanoparticles in adenovirus mediated gene delivery. Biomaterials 2009; 30: 1809-14.
9. rd Ed. Boca Raton, FL: CRC Press 2009; pp. 379-404.
10. Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc 2007; 2: 2391-411.
11. McBain SC, Yiu HHP, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 2008; 3(2): 169-80.
12. Sun, SH, Zeng H, Robinson DB, et al. Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc 2004; 126: 273-79.
13. Robinson DB, Persson HH, Zeng H et al. DNA-functionalized MFe2O4 (M = Fe, Co, or Mn) nanoparticles and their hybridization to DNA-functionalized surfaces. Langmuir 2005; 21: 3096-103.
14. Goya, GF, Lima Jr E, Arelaro AD, et al. Magnetic Hyperthermia With Fe3O4 Nanoparticles: The Influence of Particle Size on Energy Absorption. IEEE Trans Magnetics 2008; 44: 4444-47.
15. Vargas JM, Zysler RD. Tailoring the size in colloidal iron oxide magnetic nanoparticles. Nanotechnology 2005; 16: 1474-76.
16. Matijevic E, Scheiner P. Ferric hydrous oxide sols.3. preparation of uniform particles by hydrolysis of fe(iii)-chloride, fe(iii)-nitrate, and fe(iii)-perchlorate solutions. J Colloid Interface Sci 1978; 63: 509-24.
17. Verges MA., Costo R, Roca AG, et al. Uniform and water stable magnetite nanoparticles with diameters around the monodomainmultidomain limit. J Phys D-Appl Phys 2008; 41: 134003
18. Gonzalez-Fernandez MA., Torres T, Verges R, et al. Magnetic nanoparticles for power absorption: Optimizing size, shape and magnetic properties. J Solid St Chem 2009; 182: 2779-84.
19. Buerli T, Pellegrino C, Baer K, et al. Efficient transfection of DNA or shRNA vectors into neurons using magnetofection; Nat Protocols 2007; 2: 3090-101.
20. Sapet C, Laurent N, de Chevigny A, et al. High transfection efficiency of neural stem cells with magnetofection. Biotechniques 2011; 50: 187-9.
21. Pickard MR, Barraud P, Chari DM. The transfection of multipotent neural precursor/stem cell transplant populations with magnetic nanoparticles. Biomaterials 2011; 32: 2274-84.
22. Jenkins SI, Pickard MR, Granger N, Chari DM. Magnetic Nanoparticle-Mediated Gene Transfer to Oligodendrocyte Precursor Cell Transplant Populations Is Enhanced by Magnetofection Strategies. ACS Nano 2011 Jul 13. [Epub ahead of print]
23. Davidson S, Lear M, Shanley L, et al. Differential Activity by Polymorphic Variants of a Remote Enhancer that Supports Galanin Expression in the Hypothalamus and Amygdala: Implications for Obesity, Depression and Alcoholism; Neuropsychopharmacology 2011 Jun 29. doi: 10.1038/npp.2011.93. [Epub ahead of print]
24. Fallini C, Bassell GJ, Rossoll W. High-efficiency transfection of cultured primary motor neurons to study protein localization, trafficking, and function. Mol Neurodegener 2010; 5: 17.
25. Krötz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery to cultured endothelial cells. J Vasc Res 2003; 40: 425-34.
26. Chorny M, Fishbein I, Alferiev I, Levy RJ. Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells. Mol Pharm 2009; 6: 1380-87.
27. Namgung R, Singha K, Yu MK, et al. Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials 2010; 31: 4204-13.
28. Akiyama H, Ito A, Kawabe Y, Kamihira M. Genetically engineered angiogenic cell sheets using magnetic force-based gene delivery and tissue fabrication techniques. Biomaterials 2010; 31: 1251-59.
29. Holzbach T, Vlaskou D, Neshkova I, et al. Non-viral VEGF(165) gene therapy-magnetofection of acoustically active magnetic lipospheres ('magnetobubbles') increases tissue survival in an oversized skin flap model. J Cell Mol Med 2010;14: 587-99.
30. Gersting SW, Schillinger U, Lausier J, et al. Gene delivery to respiratory epithelial cells by magnetofection. J Gene Med 2004; 6: 913-922.
31. Orlando C, Castellani S, Mykhaylyk O, et al. Magnetically guided lentiviral-mediated transduction of airway epithelial cells. J Gene Med 2010; 12: 747-54.
32. Xenariou S, Griesenbach U, Ferrari S, et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006; 13: 1545-52.
33. Bhattarai SR, Kim SY, Jang KY, et al. N-hexanoyl chitosanstabilized magnetic nanoparticles: enhancement of adenoviralmediated gene expression both in vitro and in vivo. Nanomedicine 2008; 4: 146-54.
34. Wang C, Ding C, Kong M, et al. Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem Biophys Res Commun 2011; 410: 537-42.
35. Svingen T, Wilhelm D, Combes AN, et al. Ex vivo magnetofection: a novel strategy for the study of gene function in mouse organogenesis. Dev Dyn 2009; 238: 956-64.
36. rd Ed. Boca Raton FL, CRC Press 2009; pp. 761-99.
37. Verreault M, Webb MS, Murray S, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: The targets, the agents and the delivery systems. Curr Gene Ther 2006; 6 (4): 505-533.
38. Sell, S. Potential gene therapy strategies for cancer stem cells. Curr Gene Ther 2006; 6 (5): 579-591.
39. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing lowdose doxorubicin-total remission in Yoshida sarcoma-bearing rats. Eur J Cancer Clin Oncol 1983;19: 135-39.
40. Goodwin S, Peterson C, Hob C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. J Magn Magn Mater 1999; 194: 132-9.
41. Goodwin SC, Bittner CA, Peterson CL, Wong G. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol Sci.2001; 60: 177-83.
42. Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000; 60: 6641-8.
43. Lübbe AS, Bergemann C, Brock J, McClure DG. Physiological aspects in magnetic drug-targeting. J. Magn Magn Mater 1999; 194: 149-55.
44. Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres J. Drug Targeting 1999; 6: 215-28.
45. Pulfer SK, Ciccotto SL, Gallo JM. Distribution of small magnetic particles in brain tumor-bearing rats J Neuro-Oncol 1999; 41: 99-105.
46. Mykhaylyk O, Cherchenko A, Ilkin A. Glial brain tumor targeting of magnetite nanoparticles in rats J Magn Magn Mater 2001; 225: 241-7.
47. th Annual Scientific Meeting of the Society of Interventional Radiology, Salt Lake City, Utah, 2003 (Abstract); http://www.zeropresence.com/ferx/press03-31-03.htm
48. Gallo JM, Häfeli U. Preclinical experiences with magnetic drug targeting: tolerance and efficacy and clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 1997; 57: 3063-4.
49. Jahnke A, Hirschberger J, Fischer C, et al. Intra-tumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A Physiol Pathol Clin Med 2007; 54: 599-606.
50. Hüttinger C, Hirschberger J, Jahnke A, et al. Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial. J Gene Med 2008; 10: 655-67.
51. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838-41.
52. Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther 1999; 6: 1936-51.
53. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-73.
54. Carlsson T, Bjorklund T, Deniz K. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy Curr Gene Ther 2007; 7 (2): 109-20.
55. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-5.
56. Hong CS, Goins WF, Goss JR, Burton EA, Glorioso JC. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 2006; 13: 1068-79.
57. Frisella WA, O'Connor LH, Vogler CA. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol Ther 2001; 3: 351-8.
58. Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 2006; 343: 190-7.
59. Hereñu CB, Sonntag WE, Morel GR, Portiansky EL, Goya RG. The ependymal route for insulin-like growth factor-1 gene therapy in the brain. Neuroscience 2009; 163: 442-7.
60. Cua DJ, Hutchins B, LaFace DM, Stohlman SA, Coffman RL. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol 2001; 166: 602-8.
61. Triantaphyllopoulos K, Croxford J, Baker D, Chernajovsky Y. Cloning and expression of murine IFN-β and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther 1998; 5: 253-63.
62. Croxford JL, Triantaphyllopoulos K, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160: 5181-7.
63. Croxford JL, Triantaphyllopoulos KA, Neve RM, Feldmann M, Chernajovsky Y, Baker D. Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J Immunol 2000; 164: 2776-81.
64. Nishida F, Morel GR, Hereñú CB, Schwerdt JI, Goya RG and Portiansky EL. Restorative effect of intracerebroventricular Insulin-like Growth Factor-I gene therapy on motor performance in aging rats, Neuroscience 2011; 177: 185-206.
65. Hashimoto M, Hisano Y. Directional gene-transfer into the brain by an adenoviral vector tagged with magnetic nanoparticles. J Neurosci Methods 2011; 194: 316-20.
66. Hereñú CB, Brown OA, Sosa YE, et al. The neuroendocrine system as a model to evaluate experimental gene therapy. Curr Gene Ther 2006; 6: 125-9.
67. Sánchez HL, Silva LB, Portiansky EL, Goya RG, Zuccolilli GO. Impact of very old age on hypothalamic dopaminergic neurons in the female rat: A morphometric study. J Comp Neurol 2003; 458: 319-25.
68. Hereñú CB, Cristina C, Rimoldi OJ, et al. Restorative effect of Insulin-like Growth Factor-I gene therapy in the hypothalamus of senile rats with dopaminergic dysfunction. Gene Therapy 2007; 14: 237-45.
69. Morel GR, Sosa YE, Bellini MJ, et al. Glial cell line-derived neurotrophic factor gene therapy ameliorates chronic hyperprolactinemia in senile rats. Neuroscience 2010; 167: 946-53.
70. Hazel RD, McCormack EJ, Miller J, et al. Measurement of Cerebrospinal Fluid Flow in the Aqueduct of a Rat Model of Hydrocephalus. Proc Intl Soc Mag Reson Med 2006; 14: 30.
71. Matsievskiy DD, Konorova IL, Lebedeva MA. Transcranial evaluation of blood flow velocity in the basilar artery in rats by high frequency ultrasonic Doppler technique. Bull Exp Biol Med 2009; 148: 568-71.
72. Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann Thorac Surg 1968; 5: 334-39.
73. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1: 263.
74. Staudacher DL, Flugelman MY. Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient. Curr Gene Ther 2006; 6 (6): 609-23.
75. Walter DH, Cejna M, Diaz-Sandoval L, et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 2004; 110: 36-45.
76. Sharif F, Hynes SO, McMahon J, et al. Gene-eluting stents: comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther 2006; 17: 741-50.
77. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirusmediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-68.
78. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA. 1995; 92: 5855-59.
79. Leotta E, Patejunas G, Murphy G, et al. Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg. 2002; 123: 1101-13.
80. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006; 13: 1503-11.
81. Hedman M, Hartikainen J, Syvänne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and instent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-83.
82. Grines CL, Watkins MW, Mahmarian JJ, et al. Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42: 1339-47.
83. Dobrucki LW, Tsutsumi Y, Kalinowski L, et al. Analysis of angiogenesis induced by local IGF-1 expression after myocardial infarction using microSPECT-CT imaging. J Mol Cell Cardiol 2010; 48: 1071-79.
84. Mykhaylyk OM, Dudchenko NO, Dudchenko AK. Pharmacokinetics of the doxorubicin magnetic nanoconjugate in mice. Effects of the nonuniform stationary magnetic field. Ukr Biokhim Zh 2005; 77: 80-92.
85. Mah C, Zolotukhin I, Fraites TJ, Dobson J, Batich C, Byrne BJ. Microsphere-mediated delivery of recombinant AAV vectors in vitro and in vivo. Mol Ther 2000; 1: S239
86. Mah C, Fraites T J, Zolotukhin I, et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther 2002; 6: 106-12
87. Yellen BB, Forbes ZG, Halverson DS, et al. Targeted drug delivery to magnetic implants for therapeutic applications. J Magn Magn Mater 2005; 293: 647-54.
88. Rosengart AJ, Kaminski MD, Chen H, Caviness PL, Ebner AD, Ritter JA. Magnetizable implants and functionalized magnetic carriers: a novel approach for noninvasive yet targeted drug delivery. J Magn Magn Mater 2005; 293: 633-38.
89. Fernández-Pacheco R, Valdivia JG, Ibarra MR. Magnetic nanoparticles for local drug delivery using magnetic implants. Meth Mol Biol 2009; 544: 559-69.
90. Avilés MO, Mangual JO, Ebner AD, Ritter JA. Isolated swine heart ventricle perfusion model for implant assisted-magnetic drug targeting; Int J Pharm 2008; 361: 202-8.
91. Chen H, Ebner AD, Rosengart AJ, Kaminski MD, Ritter JA. Analysis of magnetic drug carrier particle capture by a magnetizable intravascular stent: 1. Parametric study with single wire correlation. J Magn Magn Mater 2004; 284: 181-94.
92. Chen A, Ebner AD, Kaminski MD, Rosengart AJ, Ritter JA. Analysis of magnetic drug carrier particle capture by a magnetizable intravascular stent-2: parametric study with multi-wire twodimensional model. J Magn Magn Mater 2005; 293: 616-32.
93. Avilés MO, Chen H, Ebner AD, Rosengart AJ, Kaminski MD, Ritter JA. In vitro study of ferromagnetic stents for implant assisted-magnetic drug targeting. J Magn Magn Mater 2007; 311: 306-11.
94. Polyak B, Fishbein I, Chorny M, et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci USA 2008; 105: 698-703.
95. Chorny M, Fishbein I, Yellen BB, et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci USA 2010; 107: 8346-51.
96. Kempe H, Kempe M; The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy; Biomaterials 2010; 31: 9499-510.
97. Drexler KE, Engines of creation. The coming era of nanotechnology. New York: Anchor Books 1986.
98. Freitas RA, Jr., Nanomedicine, Vol. IIA; Biocompatibility. Austin TX: Landes Bioscience 2003.